Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258841 | 0.90 | MRGPRX4 (0.44) | MRGPRX4FFAR1PPARDMETMEN1 | |
| SCHEMBL519275 | 0.90 | KMT2A (0.43) | FFAR1PPARDMEN1KMT2APOLB | |
| SCHEMBL10259026 | 0.87 | MRGPRX4 (0.40) | MRGPRX4FFAR1PPARDMETMEN1 | |
| SCHEMBL518822 | 0.81 | MAOB (0.42) | MRGPRX4FFAR1PPARDKMT2A | |
| SCHEMBL10258872 | 0.80 | MET (0.47) | METKMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL7784469 | 0.79 | KMT2A (0.40) | MRGPRX4FFAR1PPARDMEN1KMT2A | |
| SCHEMBL8369696 | 0.78 | PDE10A (0.42) | ALKBH1CTSVCTSL | |
| SCHEMBL18793189 | 0.76 | CYP1A2 (0.37) | METMEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL10259046 | 0.72 | PFKFB3 (0.37) | METMAPTSMN1; SMN2 | |
| SCHEMBL176858 | 0.72 | MAOB (0.59) | MRGPRX4SMN1; SMN2CTSVCTSLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8778944-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8513251-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | MRGPRX4 1809/4885FFAR1 2728/4885PPARD 749/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | MRGPRX4 1809/4885FFAR1 2728/4885PPARD 749/4885 |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | MRGPRX4 1631/4885FFAR1 3092/4885PPARD 1077/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | MRGPRX4 1577/4885FFAR1 3030/4885PPARD 1145/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | MRGPRX4 1809/4885FFAR1 2728/4885PPARD 749/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | MRGPRX4 1809/4885FFAR1 2728/4885PPARD 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.